Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon ME, Burans JP, Olson JG, Bedford P, Kitchener S, Monath TP. Belmusto-Worn VE, et al. Among authors: nichols r. Am J Trop Med Hyg. 2005 Feb;72(2):189-97. Am J Trop Med Hyg. 2005. PMID: 15741556 Clinical Trial.
Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.
Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, Nichols R, Johnson C, Cruz J, Kennedy JS, Ennis FA, Monath TP. Weltzin R, et al. Among authors: nichols r. Nat Med. 2003 Sep;9(9):1125-30. doi: 10.1038/nm916. Epub 2003 Aug 17. Nat Med. 2003. PMID: 12925845 Clinical Trial.
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P. Monath TP, et al. Among authors: nichols r. J Infect Dis. 2003 Oct 15;188(8):1213-30. doi: 10.1086/378356. Epub 2003 Oct 3. J Infect Dis. 2003. PMID: 14551893 Clinical Trial.
Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T. Guirakhoo F, et al. Among authors: nichols r. J Virol. 2004 May;78(9):4761-75. doi: 10.1128/jvi.78.9.4761-4775.2004. J Virol. 2004. PMID: 15078958 Free PMC article.
A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
Guirakhoo F, Zhang Z, Myers G, Johnson BW, Pugachev K, Nichols R, Brown N, Levenbook I, Draper K, Cyrek S, Lang J, Fournier C, Barrere B, Delagrave S, Monath TP. Guirakhoo F, et al. Among authors: nichols r. J Virol. 2004 Sep;78(18):9998-10008. doi: 10.1128/JVI.78.18.9998-10008.2004. J Virol. 2004. PMID: 15331733 Free PMC article.
During subsequent cell culture passaging of this clone for vaccine production, a single amino acid substitution (K to R) occurred in the envelope (E) protein at residue 204 (E204) (F. ...Brown, S. Brandler, C. Fournier, B. Barrere, F. Rizvi, A. Travassos, R. Nich …
During subsequent cell culture passaging of this clone for vaccine production, a single amino acid substitution (K to R) occurred in …
A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults.
Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, Nichols R, Balser JP, Currie M, Monath TP. Artenstein AW, et al. Among authors: nichols r. Vaccine. 2005 May 9;23(25):3301-9. doi: 10.1016/j.vaccine.2005.01.079. Vaccine. 2005. PMID: 15837236 Clinical Trial.
1,267 results